Phenformine [Inn-French]
Brand names,
Phenformine [Inn-French]
Analogs
Phenformine [Inn-French]
Brand Names Mixture
Phenformine [Inn-French]
Chemical_Formula
C10H15N5
Phenformine [Inn-French]
RX_link
No information avaliable
Phenformine [Inn-French]
fda sheet
Phenformine [Inn-French]
msds (material safety sheet)
Phenformine [Inn-French]
Synthesis Reference
Shapiro, Freedman, U.S. pats. 2,961,377, 3,057,780 (1960, 1962 both to U.S.V.)
Phenformine [Inn-French]
Molecular Weight
205.26 g/mol
Phenformine [Inn-French]
Melting Point
175-178 oC
Phenformine [Inn-French]
H2O Solubility
210 mg/mL
Phenformine [Inn-French]
State
Solid
Phenformine [Inn-French]
LogP
0.759
Phenformine [Inn-French]
Dosage Forms
No information avaliable
Phenformine [Inn-French]
Indication
For the reatment of type II diabetes mellitus.
Phenformine [Inn-French]
Pharmacology
Used to treat diabetes, phenformin is a biguanide (contains 2 guanidino groups) hypoglycemic agent with actions and uses similar to those of metformin (Glucophage). Both drugs work by (1) decreasing the absorption of glucose by the intestines, (2) decreasing the production of glucose in the liver, and by (3) increasing the body's ability to use insulin more effectively. More specifically, phenformin improves glycemic control by improving insulin sensitivity. Phenformin is generally considered to be associated with an unacceptably high incidence of actic acidosis. In general biguanides should be used only in stable type II diabetics who are free of liver, kidney and cardiovascular problems and who cannot be controlled with diet.
Phenformine [Inn-French]
Absorption
No information avaliable
Phenformine [Inn-French]
side effects and Toxicity
No information avaliable
Phenformine [Inn-French]
Patient Information
No information avaliable
Phenformine [Inn-French]
Organisms Affected
Humans and other mammals